CN105338996A - α胸腺肽用于脓毒症治疗的用途 - Google Patents

α胸腺肽用于脓毒症治疗的用途 Download PDF

Info

Publication number
CN105338996A
CN105338996A CN201380028974.4A CN201380028974A CN105338996A CN 105338996 A CN105338996 A CN 105338996A CN 201380028974 A CN201380028974 A CN 201380028974A CN 105338996 A CN105338996 A CN 105338996A
Authority
CN
China
Prior art keywords
sepsis
administered
days
alpha thymosin
thymosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380028974.4A
Other languages
English (en)
Chinese (zh)
Inventor
管向东
吴健锋
C·塔特希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of Sun Yat Sen University
Sciclone Pharmaceuticals LLC
Original Assignee
First Affiliated Hospital of Sun Yat Sen University
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of Sun Yat Sen University, Sciclone Pharmaceuticals LLC filed Critical First Affiliated Hospital of Sun Yat Sen University
Priority to CN201710735183.5A priority Critical patent/CN107519483A/zh
Publication of CN105338996A publication Critical patent/CN105338996A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380028974.4A 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途 Pending CN105338996A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710735183.5A CN107519483A (zh) 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710735183.5A Division CN107519483A (zh) 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途

Publications (1)

Publication Number Publication Date
CN105338996A true CN105338996A (zh) 2016-02-17

Family

ID=49261395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380028974.4A Pending CN105338996A (zh) 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途
CN201710735183.5A Pending CN107519483A (zh) 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710735183.5A Pending CN107519483A (zh) 2012-03-30 2013-03-28 α胸腺肽用于脓毒症治疗的用途

Country Status (8)

Country Link
US (5) US20130296223A1 (https=)
EP (2) EP3741386A1 (https=)
JP (6) JP2015514093A (https=)
KR (1) KR20150048663A (https=)
CN (2) CN105338996A (https=)
CA (1) CA2866435A1 (https=)
HK (1) HK1246694A1 (https=)
WO (1) WO2013149030A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
FI3781210T3 (fi) * 2018-04-20 2024-09-12 Combioxin Sa Hypotension hoito sepsiksen tai septisen sokin yhteydessä
EP4370129A1 (en) 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
TW252045B (https=) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
PL377376A1 (pl) * 2002-11-25 2006-02-06 Sciclone Pharmaceuticals, Inc. Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny
MX348936B (es) * 2005-09-29 2017-07-03 Nektar Therapeutics Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
JP2010522192A (ja) * 2007-03-21 2010-07-01 ボーシュ アンド ローム インコーポレイティド 抗菌薬耐性のバクテリアによって引き起こされる感染症を治療、軽減、寛解、又は予防するための組成物及び方法
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20130225477A1 (en) * 2010-02-25 2013-08-29 Agennix Ag Oral Lactoferrin in the Treatment of Severe Sepsis
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SUN YAT-SEN UNIVERSITY: "Efficacy of Thymosin alpha1 for Severe Sepsis (ETASS) NCT00711620", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT00711620》 *
吴建浓等: "胸腺肽α1 对严重脓毒症患者的免疫调理作用", 《中国急救医学》 *
程爱斌等: "胸腺肽α1对严重脓毒症患者细胞免疫功能的影响", 《江苏医药》 *
陈小莉等: "胸腺肽α1对脓毒症患者T细胞亚群的影响", 《中国实用医药》 *

Also Published As

Publication number Publication date
JP2019156854A (ja) 2019-09-19
HK1207314A1 (en) 2016-01-29
JP2025107346A (ja) 2025-07-17
JP2022176345A (ja) 2022-11-25
WO2013149030A2 (en) 2013-10-03
JP2017214377A (ja) 2017-12-07
HK1246694A1 (zh) 2018-09-14
US20150024994A1 (en) 2015-01-22
JP2015514093A (ja) 2015-05-18
US20240091314A1 (en) 2024-03-21
CN107519483A (zh) 2017-12-29
EP3741386A1 (en) 2020-11-25
JP2021100983A (ja) 2021-07-08
EP2841088A4 (en) 2015-10-14
CA2866435A1 (en) 2013-10-03
US20180236036A1 (en) 2018-08-23
EP2841088B1 (en) 2020-06-17
US20130296223A1 (en) 2013-11-07
US20210106656A1 (en) 2021-04-15
EP2841088A2 (en) 2015-03-04
KR20150048663A (ko) 2015-05-07

Similar Documents

Publication Publication Date Title
US20240091314A1 (en) Use of thymosin alpha for the treatment of sepsis
Eyerich et al. Chronic mucocutaneous candidiasis, from bench to bedside
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
Suzuka et al. Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis
US20170198011A1 (en) Composition for treating sepsis or septic shock comprising the peptide originated from the smad6
WO2020243787A1 (en) Anti-inflammatory agents
US20230416318A1 (en) Osteoanabolism by 14-3-3zeta
CN103648515B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
US7608589B2 (en) Peptidyl diacylglycerides
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
JP6649376B2 (ja) 肺の炎症を治療する方法
Mylonas et al. Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea
Al-Abdouh et al. Cracking Crabs Leading to Vibrio Necrotizing Fasciitis in a Male with Undiagnosed Adrenal Insufficiency
아지즈 GPCR19 agonist (TDCA) efficacy and mode of action in atopic dermatitis and rosacea
WO2024033530A1 (en) Anakinra for the treatment of post acute covid syndrome
CN104800831B (zh) 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途
CN104800829A (zh) 寡肽联合或与吗啡的组合在制备用于镇痛的药物中的用途
US20150031617A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis
Zahs Role of Myosin Light Chain Kinase in Binge Ethanol and Burn Injury-Induced Intestinal Barrier Dysfunction
CN104800827A (zh) 寡肽在制备用于提高delta阿片受体表达的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160217

WD01 Invention patent application deemed withdrawn after publication